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Abstract
Background: Previous studies have demonstrated an association between prostate-specific antigen (PSA) kinetics
and predictive value for treatment outcomes. Abiraterone acetate (AA) is a newly approved cytochrome-P450C17
inhibitor for treatment of metastatic castration-resistant prostate cancer (mCRPC), and few studies have evaluated
PSA kinetics using AA so far. Results of a study evaluating PSA kinetics in the beginning of AA and enzalutamide
responded chemotherapy-treated patients suggested different trends between the drugs. PSA kinetics of AA-treated
patients has been reported using large datasets; however, no studies which have fully evaluated PSA kinetics in the
beginning treatment. The present study aimed to assess the PSA kinetics and relationship between the PSA kinetics
and PSA progression in chemotherapy-naïve and chemotherapy-treated mCRPC patients receiving AA.
Methods: We used two Japanese phase II trial datasets: JPN-201, chemotherapy-naïve mCRPC (n = 48) and JPN-202,
chemotherapy-treated mCRPC (n= 46). PSA kinetic parameters were calculated using actual PSA values measured every
4 weeks, and a subgroup analysis was performed to evaluate the influence of early PSA response on time to PSA
progression (TTPP). In addition, we used a Cox proportional hazard model to investigate the influence of variables on TTPP.
Results: PSA declined from week 4 but took more time to achieve nadir. PSA kinetic parameters were different between
the datasets, mean time to PSA nadir was 5.3 ± 5.6 and 2.0 ± 3.4 months, and TTPP was 9.5 ± 7.4 and 3.8 ± 4.8 months in
JPN-201 and JPN-202, respectively. In the subgroup analysis of week 4 PSA decline status, Kaplan–Meier curves for TTPP
were similar between early responders and non-progression patients in JPN-201 (median, 9.2 vs. 6.5 months, respectively)
but separated in JPN-202 (median, 3.7 vs. 1.9 months, respectively). According to univariate Cox regression analysis,
achievement of PSA response (≥50 %) at week 12 was associated with TTPP in the both trials, but the hazard ratio of PSA
decline (≥30 %) at week 4 was not significant in JPN-201.
Conclusions: Our results suggest that PSA kinetics were not comparable and early PSA response showed different
association to TTPP according to prior history of chemotherapy.
Trial registration: The original trials are registered at ClinicalTrials.gov. The identifiers are; JNJ-212082-JPN-201, registered
20 December 2012 and JNJ-212082-JPN-202, registered 30January 2013.
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Background
Globally, the estimated incidence of prostate cancer was
approximately 1.4 million in 2013. There was a 3-fold
increase in this incidence from 1990 to 2013, together
with aging and population growth [1]. Since Huggins et
al. discovered that prostate cancer growth is stimulated
by androgens, castration has been the mainstay of
advanced-stage prostate cancer treatment [2]; however,
most patients develop resistance to castration.
Abiraterone acetate (AA) is a prodrug of abiraterone,
which is a first-in-class inhibitor of cytochrome-
P450C17 that plays a role in the mechanism of castra-
tion resistance by de novo androgen synthesis [3]. It is
approved with prednisone for treatment of metastatic
castration-resistant prostate cancer (mCRPC) worldwide.
AA plus prednisone significantly prolonged overall survival
(OS) compared with placebo plus prednisone for treat-
ment of chemotherapy-naïve and chemotherapy-treated
mCRPC in pivotal global trials [4, 5]. In Japan, two single-
arm, open-label, phase II trials were separately conducted
for the purpose of obtaining local registration [6, 7].
Prostate-specific antigen (PSA) is a reliable, sensitive,
and easy to measure biomarker for prostate cancer and
is therefore widely used for evaluation of treatment in
practice [8, 9]. PSA kinetics has been studied in andro-
gen deprivation therapy using anti-androgens or taxanes
to analyze its predictive value for time-dependent out-
comes such as OS and disease progression. Several stud-
ies have reported strength of PSA decline and its
predictive value for OS, although certain results were
controversial [9–11]. Recently, Caffo et al. reported the
PSA kinetics of AA and enzalutamide responders and
demonstrated different trends with regard to PSA kinetics
between the drugs in chemotherapy-treated mCRPC pa-
tients [12]. However, patient number was limited, and
PSA kinetics of chemotherapy-naïve mCRPC patients was
not reported. Xu et al. also reported PSA kinetics of AA-
treated mCRPC patients separately by chemotherapy-
naïve and -treated populations. However, PSA kinetics
within 12 weeks was not evaluated because the original
trials measured PSA values every 12 or 16 weeks [13].
Thus, PSA kinetics in AA-treated mCRPC patients has
not been fully clarified so far.
Moreover, the Prostate Cancer Clinical Trial Working
Group (PCWG2) advises to ignore early PSA changes to
avoid detecting continuing rise of PSA level and increas-
ing in size before it regress [8]. However, some re-
searchers reported early PSA decline, and its predictive
value was possibly different by patient backgrounds and
treatment [12, 14, 15]. In addition, the clinical practice
in Japan, most of mCRPC patients are primary followed
by monthly PSA testing, so, there is a potential of over
use of early response as predictive factor for efficacy re-
gardless the PCWG2 criteria.
The aims of the present study were to assess the PSA
kinetic profile, and the relationship between PSA kinet-
ics calculated based on actual PSA values measured
4 weeks and 12 weeks and PSA progression in




This post-hoc study was conducted using datasets from
two Japanese phase II trials of AA for mCRPC: JPN-201
(ClinicalTrials.gov Identifier, JNJ-212082-JPN-201) that
included chemotherapy-naïve patients (n = 48) and JPN-
202 (ClinicalTrials.gov Identifier, JNJ-212082-JPN-202)
that included patients who received docetaxel-based
chemotherapy (n = 46). Results from the original trials
are available elsewhere [6, 7]. Major inclusion criteria
were as follows: men with mCRPC aged ≥ 20 years with
a PSA level of ≥ 5 ng/mL and an Eastern Cooperative
Oncology Group Performance Status (ECOG-PS) score
of 0 or 1 for JPN-201 and 0 to 2 for JPN-202, histologi-
cally or cytologically confirmed adenocarcinoma of the
prostate without neuroendocrine differentiation or small
cell histology, and testosterone levels of ≤ 50 ng/dL by
medical or surgical castration. Eligible patients were or-
ally administered AA 1000 mg with 10-mg prednisolone
per day. For patients with medical castration, castration
was maintained by using a luteinizing hormone-
releasing hormone (LHRH) agonist throughout the
study. PSA was assessed at baseline and every 28 days
after the AA dose.
The primary endpoint of the original trials was the
proportion of patients achieving a PSA decline of ≥ 50 %
from baseline within 12 weeks of therapy in accordance
with the Prostate-Specific Antigen Working Group
criteria (PSAWG) [16].
An independent ethics committee or institutional re-
view board approved the protocols of original trials and
informed consent forms, and the trials were conducted
in accordance with the ethical principles in the Declar-
ation of Helsinki and consistent with the Good Clinical
Practices and applicable regulatory requirements. All pa-
tients or their legally acceptable representatives provided
written informed consent, which included consent for
post-hoc analysis before entering the original trials.
PSA values used in the study and definitions of PSA
kinetic parameters
We used PSA values obtained after each 28-day cycle
from baseline (day 0) to end of treatment (EOT) or
study cutoff date (the longest duration was 785 days) to
calculate the PSA kinetic parameters.
The following PSA kinetic parameters were calculated,
as defined in the present study:
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(1)Maximum percentage PSA decline (%; defined as
nadir PSA value/baseline PSA value × 100)
(2)Time to PSA nadir (months; defined as duration
from baseline to PSA nadir)
(3)Nadir PSA value (ng/mL; defined as the minimum
PSA value during the treatment period)
(4)EOT PSA value (ng/mL; defined as the last PSA
value at EOT)
(5)PSA response (≥50 %) according to PCWG2 criteria
(6)PSA response (≥30, 50, and 90 %) at week 12
according to PCWG2 criteria
(7)Time to PSA progression (TTPP; months, defined as
duration from baseline to the day of PSA
progression according to PCWG2 criteria)
The purpose of the original studies was to demon-
strate similarity with global trials, response criteria
needed to be identical with global trials used. In the
present study, we referred PCWG2 criteria instead of
PSAWG criteria, because it no longer used in the
current clinical practice.
Statistical analysis
Findings from JPN-201 and JPN-202 were separately an-
alyzed. Patient demographics, baseline characteristics,
and PSA kinetic parameters were descriptively summa-
rized using mean, standard deviation (SD), and percentage
values. The percentage PSA change was longitudinally de-
scribed based on mean (SD) and 95 % confidence intervals
(CI) at each time point to characterize the post-treatment
PSA kinetics.
We analyzed the impact of early PSA decline on
TTPP. Because treatment was repeated every 28 days,
and PSA was measured on the first day of each cycle in
JPN-201 and JPN-202, the PSA value at week 4 was the
earliest PSA value available to assess PSA transition. We
subdivided the percent PSA change at week 4 into the
following three subgroups: (1) PSA decline ≤ −30 %
(30 %-decline), (2) PSA > −30 and < 25 % (non-decline),
and (3) PSA elevation ≥ 25 % (25 %-elevation). Further-
more, TTPP was analyzed based on PSA response
(≥50 %) at week 12 according to the PCWG2 criteria. In
addition, impact of the PSA kinetic parameters on TTPP
was investigated using a Cox proportional hazard model
to obtain the hazard ratio (HR) and its 95 % CI. TTPP
curves were developed using Kaplan–Meier method.
All statistical analyses were performed using R version
3.1.0 (a language and environment for statistical computing;
R Foundation for Statistical Computing, Vienna, Austria).
Results
Baseline demographics and characteristics
In the present study, data from a total of 94 patients
were analyzed: 48 patients from JPN-201 and 46 from
JPN-202. Baseline demographics and characteristics are
summarized in Table 1. In JPN-201, the median age was
70 years, 83.3 of the patients had ECOG-PS scores of 0,
and 89.6 % had a Gleason score of ≥ 8. In JPN-202, the
median age was 71 years, 52.2, 34.8, and 13.0 % of the
patients had ECOG-PS scores of 0, 1, and 2, respectively,
and 78.3 % had a Gleason score of ≥ 8.
In JPN-202, all patients had received docetaxel-based
chemotherapy at study entry.
Abiraterone compliance, dose reducations and
interaptions
In JPN-201, 91.7 % (44/48) had > 90 % compliance with
AA. Dose reductions were required for 3 (6.3 %) pa-
tients. Dose interruptions were required for 21 (45.7 %)
patients, once for 13 and 9 patients required 2 or more
dose interruptions.
In JPN-202, 93.5 % (43/46) had > 90 % compliance
with AA. Dose reductions were required for 6 (13.0 %)
patients. Dose interruptions were required for 22
(47.8 %) patients, 8 patients required 2 or more dose
interruptions.
No patients discontinued study treatment because of
poor compliance in the both trials.
PSA kinetic parameter values
PSA values were well followed up, PSA progression was
confirmed 75 (36/48) and 10 % (5/48) was censored
within the first year in JPN-201. In JPN-202, PSA pro-
gression was confirmed 93 (43/46) and 4 % (2/46) was
censored within the first year.
In JPN-201, PSA rapidly decreased from week 4 on-
wards, and the mean PSA decline from baseline value
was 51.6 % (SD: 41.2) (Fig. 1a). Figure 1b depicts the
percentage change of PSA transition in each patient.
The PSA kinetic parameters are shown in Table 2. At
week 4, 36 patients achieved a 30 %-decline, 9 patients
showed a non-decline, and 3 patients showed a 25 %-ele-
vation. PSA responses (≥50 %) were confirmed in 28 of
36 patients who achieved 30-decline, 2 patients who
showed a non-decline, and none of the 25 %-elevation
patients. Figure 2a shows the TTPP according to the
week 4 percent PSA change subgroups. The median
TTPP was 9.2 months for 30 %-decline, 6.5 months for
non-decline, and 1.0 month for 25 %-elevation. In
addition, of the 9 non-decline patients, 1 continued to
have a PSA response and 6 showed PSA progression at
EOT. Other 2 patients were censored by discontinuing
of the treatment. Figure 2b shows TTPP according to
the PSA response (≥50 %) at week 12. The median TTPP
was 11.1 months for responders, 1.9 month for patients
with PSA progression, and 6.5 months for others (non-
response and non-progression).
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In JPN-202, the mean PSA decline at week 4 was 14.9 %
(SD: 59.1) (Fig. 1c). Figure 1d depicts the percentage change
of PSA transition for each patient. The PSA kinetic parame-
ters are shown in Table 2. At week 4, 21 patients achieved a
30 %-decline, 14 patients showed a non-decline and 11
showed a 25 %-elevation. PSA responses (≥50 %) were con-
firmed in 13 of 21 30 %-decline patients, while none of the
patients had PSA responses in the other subgroups. Figure 3a
shows the TTPP according to the subgroups; the median
TTPP was 3.7 months for 30 %-decline, 1.9 months for
non-decline, and 1.0 month for 25 %-elevation. All non-
30 %-decline patients had PSA progression at EOT. Figure 3b
shows the TTPP according to PSA response (≥50 %) at week
12. The median TTPP was 4.6 months for responders,
1.9 months for patients with PSA progression, and
4.6 months for others (non-response and non-progression).
Results of univariate Cox analyses
Table 3 shows the results of univariate Cox regression
analyses for TTPP. In JPN-201, all variables showed
significance except PSA decline (≥30 %) at week 4. In
JPN-202, all variables showed significance except nadir
PSA value and PSA response (≥90 %) at week 12.
Discussion
In this post-hoc analysis, we first assessed the PSA kin-
etic profile in AA plus prednisolone-treated mCRPC pa-
tients. There was a clear difference in the PSA kinetic
profile between chemotherapy-naïve and chemotherapy-
treated patients. The majority of chemotherapy-naïve
patients showed a rapid PSA decline at week 4, and
additional 4 months were needed to reach PSA nadir.
On the other hand, the majority of chemotherapy-
treated patients showed non-decline or 25 % elevation
at week 4, and the mean time to reach PSA nadir
was 2.0 months. Moreover, the percent change in the
PSA values in chemotherapy-treated patients tended
to be larger, and most of the patients experienced PSA
progression within a year after treatment initiation (Fig. 1).
The mean TTPP was approximately 4 months, which was
Table 1 Baseline patient demographics and characteristics
Chemotherapy-naive Chemotherapy-treated
JPN-201 (n = 48) JPN-202 (n = 46)
Median age (range), years 70 (46–89) 71 (51–83)
Gleason score
< 7 0 % 0 %
7 8.3 % 17.4 %
≥ 8 89.6 % 78.3 %
Unknown 2.1 % 4.3 %
ECOG-PS score
0 83.3 % 52.2 %
1 16.7 % 34.8 %
2 – 13.0 %
Extent of disease
Bone 91.7 % 95.7 %
Hepatic 2.1 % 4.3 %
Lymphatic 39.6 % 37.0 %
Pulmonary 0 % 10.9 %
Other 0 % 6.5 %
Median months from initiating LHRH agonist to first dose (range) 21.91 (6.2–191.6) 41.23 (4.4–182.8)
Median baseline PSA (range), ng/mL 31.40 (6.0–469.0) 147.00 (7.2–1450.0)
Median baseline hemoglobin (range), g/dL 12.85 (10.2–15.2) 11.80 (9.0–14.9)
Median LDH (range), IU/L 212.0 (164–1045) 211.0 (122–723)
Median alkaline phosphatase (range), IU/L 292.0 (139–2643) 327.0 (69–2991)
No. of previous chemotherapy regimens
1 – 39.1 %
2 – 60.9 %
ECOG-PS Eastern Corporative Oncology Group Performance Status, LDH lactate dehydrogenase, LHRH luteinizing hormone-releasing hormone, PSA
prostate-specific antigen
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approximately half of the value reported in JPN-201
(9.5 months). Differences in characteristics of patient
populations with mCRPC may impact the PSA kinetic
profile, and such PSA kinetic differences could mainly
be associated with previous history of chemotherapy.
The mechanisms related to the differences in PSA
kinetic profiles between chemotherapy-naïve and
chemotherapy-treated patients are unclear; however, it
is recommended that PSA kinetics would be separately
evaluated according to prior history of chemotherapy.
Caffo et al. reported that the time to PSA nadir in re-
sponders among chemotherapy-treated mCRPC patients
was 15.5 weeks with AA but 7.0 weeks with enzalutamide
[12]. Moreover, the anti-tumor effects of both drugs are
Fig. 1 Percent PSA transition from baseline to month 13. a Mean percent PSA change in JPN-201, (n). b Percent PSA change for each patient in
JPN-201; green, PSA≤ −30 % (30 %-decline); blue, −30 % < PSA < 25 % (non-decline); red, PSA≥ 25 % (25 %-elevation) according to PSA change
at week 4. c Mean percent PSA change in JPN-202, (n). d Percent PSA change for each patient in JPN-202; green, PSA≤ −30 % (30 %-decline);
blue, −30 % < PSA < 25 % (non-decline); red, 25 %≥ PSA (25 %-elevation) according to PSA change at week 4. Data are expressed as mean ± 95 % CI.
Note: PSA changes of≥ 300 % and those after month 13 are not shown
Table 2 PSA kinetic parameters, mean ± SD (95 % CI)
JPN-201 (n = 48) JPN-202 (n = 46)
Chemotherapy-naive Chemotherapy-treated
Maximum % PSA decline 64.4 ± 38.3 (53.3–75.5) 19.7 ± 59.4 (2.0–37.3)
Time to PSA nadir (months) 5.3 ± 5.6 (3.7–6.9) 2.0 ± 3.4 (1.0–3.0)
Nadir PSA value (ng/mL) 19.5 ± 28.3 (11.3–27.7) 184.9 ± 282.3 (101.0–268.7)
PSA response (≥30 %) at week 12, n (%; 95 % CI) 35 (72.9; 58.2–84.7) 15 (32.6; 19.5–48.0)
PSA response (≥50 %) at week 12, n (%; 95 % CI) 29 (60.4; 45.3–74.2) 13 (28.3; 16.0–43.5)
PSA response (≥90 %) at week 12, n (%; 95 % CI) 9 (18.8; 8.9–32.6) 2 (4.3; 0.5–14.8)
PSA response (≥50 %) in treatment period, n (%; 95 % CI) 30 (62.5; 47.48–76.0) 13 (28.3; 16.0–43.5)
Time to PSA progression (months) 9.5 ± 7.4 (7.4–11.6) 3.8 ± 4.8 (2.4–5.2)
PSA prostate-specific antigen, CI confidence interval, SD standard deviation
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derived from different mechanisms of action; abiraterone
inhibits androgen synthesis at non-gonadal sites (adrenal
gland and intratumorally) to reduce androgens to below
castrate concentrations, while enzalutamide, an anti-
androgen, directly binds androgen receptors to inhibit an-
drogen receptor nuclear translocation [17]. These differ-
ences in the mechanisms of action might affect PSA
kinetics.
In the present study, some patients showed a continu-
ous stable level of PSA (Fig. 1b). In JPN-201, of the 9
(19 %) patients categorized as non-decline, most did not
show large PSA elevation within 12 months. The TTPP
curves were similar between non-decline and 30 %-de-
cline patients (Fig. 2a). Thus, for chemotherapy-naïve
patients without PSA progression at week 4, there would
be a clinically similar chance of benefit from AA treat-
ment. This is also supported by the result of Cox regres-
sion analysis, HR was significant for PSA response
(≥50 %) at week 12 but not for PSA decline (≥30 %) at
week 4 (Table 3).
On the other hand, in JPN-202, the non-decline TTPP
curve was shorter than that of 30 %-decline and differed
from that of 25 %-elevation (Fig. 3a). A half of the non-
decline patients had rapid PSA progression; however,
another half of the patients showed continuous stable
levels of PSA (Fig. 1d), suggesting that patients with
non-decline still had some potential of obtaining a clin-
ical benefit from the treatment. The TTPP curves based
on PSA response at week 12 were close between re-
sponders and patients with non-progression (Fig. 3b).
Overall, further observation is recommended for patients
in both population regardless obtaining PSA elevation at
week 4.
In addition, temporal PSA elevation was recently re-
ported with docetaxel treatment [18], which led to the
phenomenon being referred to as “PSA flare,” indicating
a PSA elevation with initiation of an LHRH agonist. PSA
flares were also reported with AA treatment [19, 20].
According to the definition by Olbert et al., wherein a
PSA flare is defined as initially rising PSA under therapy,
dropping thereafter to values below baseline, 3 of 9 non-
decline patients (Fig. 1b; blue lines) in JPN-201and 1 of
21 in JPN-202 (Fig. 1d; blue lines) were considered to
have a PSA flare. PSA transition in such patients showed
slow PSA elevations for 2 months, which declined below
baseline levels within 1 to 2 months after the peak
level. In taxane-based chemotherapy, the pattern of
flare-up was slightly different. In the chemotherapy-
a b
Fig. 2 Kaplan–Meier curves for time to PSA progression in JPN-201. a green, PSA≤ −30 % (30 %-decline); blue, −30 % < PSA < 25 % (non-decline);
red, PSA≥ 25 % (25 %-elevation) according to PSA change at week 4. b green, PSA response (≥50 %); blue, PSA non-response/progression; red,
PSA progression according to PSA response at week 12
a b
Fig. 3 Kaplan–Meier curves for time to PSA progression in JPN-202. a green, PSA≤−30 % (30 %-PSA-decline); blue, −30 % < PSA < 25 % (non-decline);
red, PSA≥ 25 % (25 %-elevation) according to PSA change at week 4. b green, PSA response (≥50 %); blue, PSA non-response/progression; red, PSA
progression according to PSA response at week 12
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related PSA flare, a peak PSA level was reached
within 1 month after the first dose, and peak PSA
levels were detected 1 to 2 months earlier than in the
present study [18, 21, 22].
In general, elevated or stable PSA levels are a key decision
factor for treatment change in routine clinical practice.
Based on the aforementioned results, careful consideration
is recommended for evaluation of the efficacy and decision
for treatment change in AA treatment.
Some limitations of the present study are as follows:
TTPP is a well-known surrogate endpoint for OS and is
easy to follow-up in clinical practice [8]. In the present
study, investigation of OS was inappropriate because
patient number and number of events were limited.
Therefore, we alternatively evaluated TTPP. Nonethe-
less, the primary endpoint in both JPN-201 and JPN-
202 was PSA response rate at week 12; however, patient
number was insufficient to apply statistical testing to
analyze TTPP between the subgroups. Especially, pa-
tient number of non-30 %-decline was limited (11 in
chemotherapy-naïve and 25 in chemotherapy-treated
population). Moreover, in clinical practice, a wide
variety of prior therapies, patient conditions, and con-
comitant use of drugs may have a potential impact on
PSA kinetic profiles; it will therefore be important to
reconfirm these results in clinical practice.
Conclusions
Our results suggest that PSA kinetics and impact of
early PSA decline on TTPP were not comparable and
early PSA response showed slightly different association
to TTPP according to prior history of chemotherapy.
However, this is simply a descriptive study for which
practice changing assessment of response or predictor of
failure just cannot be made, further studies are war-
ranted to confirm these results.
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